Grace Therapeutics GTx-104 Phase 3 STRIVE-ON Trial Results Accepted for AAN 2026 Presentation

Key Takeaways

• Grace Therapeutics’ STRIVE-ON Phase 3 safety trial results for GTx-104 accepted for presentation at American Academy of Neurology 2026
• GTx-104 is a novel injectable nimodipine formulation targeting aneurysmal subarachnoid hemorrhage, addressing significant unmet medical needs
• AAN presentation will provide critical safety data for the late-stage neurology drug candidate

---

Grace Therapeutics Advances GTx-104 Development with Major Conference Presentation

Grace Therapeutics, Inc. (Nasdaq: GRCE) announced April 14, 2026, that abstract results from its STRIVE-ON Phase 3 Safety Trial for GTx-104 have been accepted for presentation at the American Academy of Neurology (AAN) 2026 conference.

About GTx-104 and Aneurysmal Subarachnoid Hemorrhage

GTx-104 represents a clinical-stage, novel injectable formulation of nimodipine specifically developed for intravenous infusion in patients with aneurysmal subarachnoid hemorrhage (aSAH). This neurological condition affects thousands of patients annually and represents a significant area of unmet medical need.

The Princeton, New Jersey-based late-stage biopharmaceutical company has focused its development efforts on addressing critical gaps in aSAH treatment options. Current treatment approaches for this serious neurological condition remain limited, making GTx-104’s development particularly significant for the neurology community.

Clinical Trial Significance

The STRIVE-ON Phase 3 Safety Trial represents a crucial milestone in GTx-104’s development pathway. Phase 3 trials typically evaluate safety and efficacy in larger patient populations, providing regulatory agencies with comprehensive data needed for approval decisions.

Acceptance at AAN 2026 indicates that the trial results meet the conference’s rigorous scientific standards. The American Academy of Neurology conference serves as a premier platform for presenting breakthrough neurology research to the global medical community.

Market Impact and Future Outlook

For Grace Therapeutics, this presentation opportunity provides valuable visibility within the neurology specialist community. The company’s focus on addressing unmet needs in aSAH positions GTx-104 as a potentially important addition to current treatment protocols.

The injectable nimodipine formulation approach represents an innovative delivery method that could offer advantages over existing oral formulations, particularly in critically ill aSAH patients who may have difficulty with oral medications.

Investors and healthcare professionals will closely monitor the AAN presentation for detailed safety data and potential efficacy signals that could inform GTx-104’s regulatory pathway and commercial prospects.

---

Frequently Asked Questions

What does this mean for aneurysmal subarachnoid hemorrhage patients?

The STRIVE-ON trial results being presented at AAN 2026 could provide evidence for a new treatment option. GTx-104’s injectable formulation may offer advantages for critically ill aSAH patients who cannot take oral medications.

When will GTx-104 be available to patients?

GTx-104 is still in Phase 3 trials. Following successful trial completion and regulatory review, the drug could potentially reach patients within 1-3 years, depending on FDA approval timelines.

How does GTx-104 compare to existing aSAH treatments?

GTx-104 is a novel injectable formulation of nimodipine, which may provide better delivery and dosing control compared to oral nimodipine formulations currently used in aSAH treatment protocols.